Logo do repositório
 
Publicação

A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe

2020Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorLazarus, Jeffrey V.
dc.contributor.authorEkstedt, Mattias
dc.contributor.authorMarchesini, Giulio
dc.contributor.authorMullen, Jillian
dc.contributor.authorNovak, Katja
dc.contributor.authorPericàs, Juan M.
dc.contributor.authorRoel, Elena
dc.contributor.authorRomero-Gómez, Manuel
dc.contributor.authorRatziu, Vlad
dc.contributor.authorTacke, Frank
dc.contributor.authorCortez-Pinto, Helena
dc.contributor.authorAnstee, Quentin M.
dc.date.accessioned2023-03-07T11:40:36Z
dc.date.available2023-03-07T11:40:36Z
dc.date.issued2020
dc.description© 2019 European Association for the Study of the Liver. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).pt_PT
dc.description.abstractBackground & aims: Non-alcoholic fatty liver disease (NAFLD) is a growing public health problem worldwide and has become an important field of biomedical inquiry. We aimed to determine whether European countries have mounted an adequate public health response to NAFLD and non-alcoholic steatohepatitis (NASH). Methods: In 2018 and 2019, NAFLD experts in 29 European countries completed an English-language survey on policies, guidelines, awareness, monitoring, diagnosis and clinical assessment in their country. The data were compiled, quality checked against existing official documents and reported descriptively. Results: None of the 29 participating countries had written strategies or action plans for NAFLD. Two countries (7%) had mentions of NAFLD or NASH in related existing strategies (obesity and alcohol). Ten (34%) reported having national clinical guidelines specifically addressing NAFLD and, upon diagnosis, all included recommendations for the assessment of diabetes and liver cirrhosis. Eleven countries (38%) recommended screening for NAFLD in all patients with either diabetes, obesity and/or metabolic syndrome. Five countries (17%) had referral algorithms for follow-up and specialist referral in primary care, and 7 (24%) reported structured lifestyle programmes aimed at NAFLD. Seven (24%) had funded awareness campaigns that specifically included prevention of liver disease. Four countries (14%) reported having civil society groups which address NAFLD and 3 countries (10%) had national registries that include NAFLD. Conclusions: We found that a comprehensive public health response to NAFLD is lacking in the surveyed European countries. This includes policy in the form of a strategy, clinical guidelines, awareness campaigns, civil society involvement, and health systems organisation, including registries. Lay summary: We conducted a survey on non-alcoholic fatty liver disease with experts in European countries, coupled with data extracted from official documents on policies, clinical guidelines, awareness, and monitoring. We found a general lack of national policies, awareness campaigns and civil society involvement, and few epidemiological registries.pt_PT
dc.description.sponsorshipFinancial support for this research was provided by the EASL International Liver Foundation through grants from Gilead Sciences Europe Ltd., Allergan Pharmaceutical International Ltd., Bristol-Myers-Squibb Company, Pfizer Inc., and Resoundant Inc. JVL is a Miguel Servet-funded researcher at ISGlobal, Hospital Clínic, University of Barcelona. QMA and VR are members of the EPoS (Elucidating Pathways of Steatohepatitis) consortium funded by the Horizon 2020 Framework Program of the European Union under Grant Agreement 634413. QMA, VR, HCP, ME, MRG, HCP are members of the LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) consortium funded by the IMI2 Program of the European Union under Grant Agreement 777377. QMA is a Newcastle NIHR Biomedical Research Centre investigator.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationJ Hepatol. 2020 Jan;72(1):14-24pt_PT
dc.identifier.doi10.1016/j.jhep.2019.08.027pt_PT
dc.identifier.eissn1600-0641
dc.identifier.issn0168-8278
dc.identifier.urihttp://hdl.handle.net/10451/56556
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevierpt_PT
dc.relationElucidating Pathways of Steatohepatitis
dc.relationLiver Investigation: Testing Marker Utility in Steatohepatitis
dc.relation.publisherversionhttps://www.sciencedirect.com/journal/journal-of-hepatologypt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectEuropept_PT
dc.subjectGuidelines as topicpt_PT
dc.subjectHealth Policypt_PT
dc.subjectNon-alcoholic fatty liver disease (NAFLD)pt_PT
dc.subjectNon-alcoholic steatohepatitis (NASH)pt_PT
dc.subjectReviewpt_PT
dc.titleA cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardNumber634413
oaire.awardNumber777377
oaire.awardTitleElucidating Pathways of Steatohepatitis
oaire.awardTitleLiver Investigation: Testing Marker Utility in Steatohepatitis
oaire.awardURIinfo:eu-repo/grantAgreement/EC/H2020/634413/EU
oaire.awardURIinfo:eu-repo/grantAgreement/EC/H2020/777377/EU
oaire.citation.endPage24pt_PT
oaire.citation.issue1pt_PT
oaire.citation.startPage14pt_PT
oaire.citation.titleJournal of Hepatologypt_PT
oaire.citation.volume72pt_PT
oaire.fundingStreamH2020
oaire.fundingStreamH2020
person.familyNameCortez-Pinto
person.givenNameHelena
person.identifier.ciencia-idA01C-0511-C986
person.identifier.orcid0000-0002-8537-8744
project.funder.identifierhttp://doi.org/10.13039/501100008530
project.funder.identifierhttp://doi.org/10.13039/501100008530
project.funder.nameEuropean Commission
project.funder.nameEuropean Commission
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication91fdb4b3-d491-4e67-94ff-dcf5013fa1a7
relation.isAuthorOfPublication.latestForDiscovery91fdb4b3-d491-4e67-94ff-dcf5013fa1a7
relation.isProjectOfPublication7879c6f3-1779-4b00-83e9-1a6154dcddac
relation.isProjectOfPublication7c278bce-09c1-41f0-a37d-0adf606b1320
relation.isProjectOfPublication.latestForDiscovery7c278bce-09c1-41f0-a37d-0adf606b1320

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Cross_fatty.pdf
Tamanho:
679.21 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

FM-LN-Artigos em Revistas Internacionais